Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hunter

Showing results (1181-1190 of 1,249) with videos related to

Pageof 125
Sort By:
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Eclinicalmedicine|November 22, 2021
Corrigendum to "Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial." [EClinicalMedicine 37 (2021) 100981]Vinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemiaJenny Y Sun, Lian Xu, Hsuyi Tseng, et al.
BMC Medical Research Methodology|May 7, 2010
Methods for determining disease burden and calibrating national surveillance data in the United Kingdom: the second study of infectious intestinal disease in the community (IID2 study)Sarah J O'Brien, Greta Rait, Paul R Hunter, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Journal of Economic Entomology|October 22, 2025
Chemical management strategies for the invasive Jorō spider, Trichonephila clavata (Araneae: Araneidae)Angela Chuang, David R Nelsen, Michael I Sitvarin, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Eclinicalmedicine|July 5, 2021
Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trialVinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter, et al.
Heart Rhythm|May 21, 2013
Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: a 2-center studyL C Malcolme-Lawes, C Juli, R Karim, et al.
Pageof 125

Showing results (1181-1190 of 1,249) with videos related to

Sort By:
Pageof 125
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Eclinicalmedicine|November 22, 2021
Corrigendum to "Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial." [EClinicalMedicine 37 (2021) 100981]Vinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemiaJenny Y Sun, Lian Xu, Hsuyi Tseng, et al.
BMC Medical Research Methodology|May 7, 2010
Methods for determining disease burden and calibrating national surveillance data in the United Kingdom: the second study of infectious intestinal disease in the community (IID2 study)Sarah J O'Brien, Greta Rait, Paul R Hunter, et al.
British Journal of Haematology|November 29, 2017
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P Treon, Joshua Gustine, Lian Xu, et al.
Journal of Economic Entomology|October 22, 2025
Chemical management strategies for the invasive Jorō spider, Trichonephila clavata (Araneae: Araneidae)Angela Chuang, David R Nelsen, Michael I Sitvarin, et al.
Blood|November 16, 2023
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemiaJorge J Castillo, Andrew R Branagan, David Sermer, et al.
Eclinicalmedicine|July 5, 2021
Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trialVinicius Fontanesi Blum, Sérgio Cimerman, James R Hunter, et al.
Heart Rhythm|May 21, 2013
Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: a 2-center studyL C Malcolme-Lawes, C Juli, R Karim, et al.
Pageof 125